TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05139875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone Dipropionate / Betamethasone Sodium Phosphate
Description: Single intra-articular Betamethasone Dipropionate / Betamethasone Sodium Phosphate (Diprospan) injections to affected knee

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide 40mg/mL
Description: Single intra-articular Triamcinolone Acetonide injections to affected knee
Study: NCT05493774

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-person virtual reality simulation scenario training
Description: Using multi-person virtual reality simulation scenario training to evaluate the learning effectiveness of nursing care for emergency burn and scald patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multi-person high-fidelity simulation scenario training
Description: Using multi-person high-fidelity simulation scenario training to evaluate the learning effectiveness of nursing care for emergency burn and scald patients.
Study: NCT05780489

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Determination of progesterone and oestradiol
Description: Blood and saliva samples will be taken for determination of progesterone and oestradiol hormones.
Study: NCT06571448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR750 tablet
Description: SR750 high dose BID orally for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR750 tablet
Description: SR750 low dose BID orally for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05556720

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfizer Bivalent COVID-19 Vaccine
Description: One or Two doses three months apart, per manufacturer's recommendations.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfizer Bivalent COVID-19 Vaccine
Description: One or Two doses three months apart, per manufacturer's recommendations.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfizer Bivalent COVID-19 Vaccine
Description: One or Two doses three months apart, per manufacturer's recommendations.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna Bivalent mRNA vaccine
Description: One or Two doses three months apart, per manufacturer's recommendations.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna Bivalent mRNA vaccine
Description: One or Two doses three months apart, per manufacturer's recommendations.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna Bivalent mRNA vaccine
Description: One or Two doses three months apart, per manufacturer's recommendations.
Study: NCT05688748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dengue self-monitoring system
Description: The system has a symptom monitoring algorithm whereby patient would be asked to report their symptoms thrice daily (9am, 2pm and 8pm). The algorithm is developed by the researchers which consist of primary care doctors, emergency physician and infectious disease specialists. If the patient reports warning symptoms (persistent vomiting, persistent diarrhoea, abdominal pain, bleeding, difficulty breathing, feel like fainting, difficulty carrying out usual activities, drowsiness, reduced urine output and reduced urine output), the system will advise patients to seek earlier medical care instead of waiting for the scheduled appointment the next day/other days.
Study: NCT06041984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: Intravenous injection of glycopyrrolate 0.2mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous injection of saline 1ml
Study: NCT05923164

Intervention type: DIAGNOSTIC_TEST
Intervention: Patient And Observer Scar Assessment Scale ( Observer Subscale)
Description: This assesment tool consists of two different scales evaluated by the observer and the patient.The observer scale rates five variables, which include vascularity, pigmentation, thickness, relief, pliability and surface area, between 1-10 points (1:normal skin). The total score ranges from 5 to 50.
Study: NCT06543264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Cryotherapy is a pain treatment that uses a method of localized freezing temperatures to deaden an irritated nerve. Cryotherapy is also used as a method of treating localized areas of some cancers (called cryosurgery), such as prostate cancer and to treat abnormal skin cells by dermatologists
Study: NCT06036758

Intervention type: DIAGNOSTIC_TEST
Intervention: VIDAS® NEPHROCLEAR™ CCL14 Test
Description: Urine samples previously collected from persons with stage 2/stage 3 AKI will be tested using the VIDAS® NEPHROCLEAR™ CCL14 Test
Study: NCT05287139

Intervention type: OTHER
Intervention: Quality of Life
Description: Assessment of patients' quality of life using the EORTC QLQ-C30 and EORTC-QLQ-BR 23 questionnaires

Intervention type: OTHER
Intervention: Quality of Life
Description: Assessment of patients' quality of life using the EORTC QLQ-C30 and EORTC-QLQ-BR 23 questionnaires
Study: NCT04947579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-99677
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-99677
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-99677
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-99677
Description: Oral

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT06544083

Intervention type: DIAGNOSTIC_TEST
Intervention: Proteomics
Description: Proteomic is performed on all blood samples.

Intervention type: DIAGNOSTIC_TEST
Intervention: Proteomics
Description: Proteomic is performed on all blood samples.

Intervention type: DIAGNOSTIC_TEST
Intervention: Proteomics
Description: Proteomic is performed on all blood samples.
Study: NCT06192251

Intervention type: BEHAVIORAL
Intervention: Lifestyle Medicine
Description: Education and support for lifestyle modification to improve health conditions
Study: NCT05306379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Oral dose 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voclosporin
Description: Oral dose 23.7 mg twice daily
Study: NCT04972656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: Titration:~Monotherapy using ambrisentan will be initialized at a beginning dose of 5 mg (once daily). Drug intake is scheduled at the morning. After 4 weeks monitoring, the dose of ambrisentan will be uptitrated to 10 mg once daily. Otherwise, if intolerability is indicated, a dose of 5 mg (once daily) will be maintained through the study duration.~Maximum dose allowed: not to exceed 10 mg/day.~Administration:~Ambrisentan will be administered orally with or without food intake.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet (one to two tablets corresponding to one to two verum tablets).~Administration:~Placebo will be administrated orally with or without food intake in the morning.
Study: NCT04973956

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation
Description: This group will perform the APMR. This intervention consists of a standardized 20 min session in which subjects are asked to sequentially tense and relax various muscle groups. To do so, participants will listen to an audio with relaxation instructions while seated in a reclining seat and dimmed lighting.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: No intervention
Study: NCT04921033

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EEN (Nestle Modulen®)
Description: 35kcal/kg/day for every patient

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standart of care
Description: * Budesonide 9mg/day for mild disease~* Prednisolone 1mg/kg, maximum 40mg/day in decreasing doses (40mg for 4 weeks followed by a fixed taper for 6 weeks) for moderate-to-severe disease for 12 weeks.~* Patients with moderate to severe disease in the steroid group will also receive 2mg/kg azathioprine. The dose of azathioprine will be adjusted according to abnormalities of white blood cell (WBC) count, platelet count, liver function tests (LFTs; i.e. alanine transaminase \[ALT\], aspartate transaminase \[AST\], alkaline phosphatase), lipase, blood urea nitrogen (BUN), and serum creatinine.
Study: NCT03862599

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extra-corporeal shockwave therapy (ESWT)
Description: low-intensity extra-corporeal shockwave therapy

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Extra-corporeal shockwave therapy (ESWT)
Description: low-intensity extra-corporeal shockwave therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Cialis and vacuum pump

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard care
Description: Cialis and vacuum pump
Study: NCT05636878

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Intervention Team in Perinatal Psychiatry (EMPPer)
Description: The Mobile Intervention Team in Perinatal Psychiatry consists in going towards the most excluded patients, changing the organization of care compared to the current practice and facilitating access to care for the most vulnerable populations
Study: NCT05152342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stigma Awareness Training for Legal System Staff
Description: Multilevel intervention package addressing stigma associated with substance use and criminal involvement for staff and justice-involved clients enrolled in a diversion treatment program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy for self-stigma
Description: Multilevel intervention package addressing stigma associated with substance use and criminal involvement for staff and justice-involved clients enrolled in a diversion treatment program.
Study: NCT05635825

Intervention type: OTHER
Intervention: Observational Survey
Description: Collection of a 4-day food record
Study: NCT06066619

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 100% Cranberry Juice
Description: 100% Cranberry juice will be provided from Ocean Spray Company.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 100% Cranberry Juice + 200 mg L-theanine
Description: 100% Cranberry Juice + 200 mg L-theanine will be provided from Ocean Spray Company.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Juice
Description: Placebo juice will be provided from Ocean Spray Company to match the appearance, taste, and calories of the cranberry juice.
Study: NCT04999878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib, Etoposide, Dexamethasone, Gemcitabine, Pegaspargase, cis-platinum
Description: All enrolled patients will receive a regimen containing Ruxilitinib, Etoposide, Dexamethasone, Gemcitabine, Pasparase and Platinum for 28 days. The specific medication is as follows:~Ruxilitinib 10 mg, bid, d1-28, P.O. Etoposide 100mg per week, two weeks, ivgtt Dexamethasone, 15mg/(m²·d)，d1-12，10 mg/ (m²·d) ，d13-14，5 mg/ (m²·d) ，d15-21，2.5mg/(m²·d)，d22-28，ivgtt or P.O.~Gemcitabine, 0.5 g/m², d8, ivgtt Pegaspargase, 2500IU/m², d9, im Platinum, 20mg/m² d10 d11, ivgtt After the treatment, patients will be given disease specific chemotherapy regimen to treat lymphoma according to patient's different lymphoma subtype.
Study: NCT05895136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human albumin
Description: Human albumin solution is made from pooled human plasma. It is widely used as a plasma-expander in several disease conditions, such as liver cirrhosis and critically ill patients.~ATC-Code: B05AA01

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Enoxaparin is a drug that belongs to the group of anticoagulants. It exerts its antithrombotic activity by binding to antithrombin III (AT III). ATC-Code: B01AB05

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical treatment
Description: SMT will be considered non-study medication and is not specified in the protocol.
Study: NCT06362512

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual-task training
Description: participants receive three 60-minute COGMOTION dual-task exercise sessions per week for six consecutive weeks.
Study: NCT05386017

Intervention type: OTHER
Intervention: Anthropometric measurements and sociodemographic and health data collection
Description: Anthropometric measurements : weight, height, abdominal circumference, abdominal circumference, percentage of fat mass, percentage of lean body mass, and estimated visceral fat level, visceral fat.~Sociodemographic and health data collection : Collect over a 7-year period changes in physical activity practices, eating habits and behaviours and the motivations for these changes or the initiatives to change the weight, Perceived stress and control, Life courses, events and impact perception Status, level of education, social background, place of residence, relationship with family Diet, tobacco and alcohol consumptions Physical activity behaviour and barriers, sedentary behaviour, quality of life perceived, exploring possible behavioural eating disorders, anxiety, depression
Study: NCT05018923

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole
Description: 20mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: 20mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth potassium citrate
Description: 0.6g bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth potassium citrate
Description: 0.6g bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: 0.4g qid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: 0.4g qid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: 0.1g bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline
Description: 0.5g qid
Study: NCT05218343

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EHR-based nudge interventions
Description: Change/introduction of default drug and frequency during electronic prescribing of high-risk drugs for a patient aged ≥65 years
Study: NCT05553457

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Testing of MyHand-SCI Device
Description: Subjects will attend 1-20 sessions (approximately 90 minutes) to trial the MyHand-SCI device, including a variety of controls and components.
Study: NCT06015074

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: patients in Propofol group receive sufentanil(0.1ug/kg)+ propofol (1.5-2mg/kg) for anesthesia induction, and continuous infusion of propofol 5mg/kg/h for anesthesia maintain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofol
Description: patients in Ciprofol group receive sufentanil(0.1ug/kg)+ ciprofol(0.4-0.5mg/kg) for anesthesia induction, and continuous infusion of ciprofol 0.8mg/kg/h for anesthesia maintain.
Study: NCT06238687

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STRO-002
Description: STRO-002 is an Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the anti-tumor activity of cytotoxic drugs.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STRO-002
Description: STRO-002 is an Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the anti-tumor activity of cytotoxic drugs.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STRO-002
Description: STRO-002 is an Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the anti-tumor activity of cytotoxic drugs.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STRO-002
Description: STRO-002 is an Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the anti-tumor activity of cytotoxic drugs.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STRO-002
Description: STRO-002 is an Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the anti-tumor activity of cytotoxic drugs.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STRO-002
Description: STRO-002 is an Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the anti-tumor activity of cytotoxic drugs.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STRO-002
Description: STRO-002 is an Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the anti-tumor activity of cytotoxic drugs.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STRO-002
Description: STRO-002 is an Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the anti-tumor activity of cytotoxic drugs.
Study: NCT06362512

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Single-task training
Description: participants receive 30-minute single motor tasks with 30-minute single cognitive tasks three times per week for six consecutive weeks.The cognitive and mobility exercises will be the same as those in the dual-task group, but they will be performed separately.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Upper limb strengthening exercise
Description: participants receive upper limb strengthening exercise for 30 minutes and flexibility exercises for 30 minutes three times per week for six consecutive weeks. The training is performed in sitting or standing position and no cognitive load will be added.
Study: NCT04895865

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RPE-based load and repetition number selection
Description: Providing trainees with choices regarding the load and the number of repetitions to be performed per set and exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Predetermined load and number of repetitions
Description: Trainees predetermine the load and perform ten repetitions per set and exercise
Study: NCT05362565

Intervention type: BIOLOGICAL
Intervention: Salivary Sampling
Description: The DNA study will be carried out from saliva sample~1 saliva sample per patient will be performed at the inclusion visit
Study: NCT06156423

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor control exercise
Description: Motor control exercises include stabilization exercises for the scapula with external focus by activating the correct alignment and kinetic chain by providing verbal feedback and visual feedback.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard exercise
Description: The standard rehabilitation group received a rehabilitation program via video call 3 days a week for 12 weeks.
Study: NCT04987762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adhansia XR
Description: Methylphenidate extended-release capsules taken once daily (12.5 mg, 25 mg, 35 mg, 45 mg, 55 mg, and 70 mg)
Study: NCT05684627

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fast mimicking diet group
Description: Test group will be assigned to follow one cycle of a fasting mimicking diet the same day after receiving the full mouth non surgical periodontal treatment. The FMD program is a plant-based diet program designed to attain fasting-like effects while providing both macro- and micronutrients to minimize the burden of fasting and adverse effects. The FMD consist 5 days regimen that provides approximately 1.100 kilocalories for the first day ; approximately 750 kilocalories per day for the second to the fifth day. FMD group will need 5 visits.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normal diet group
Description: Normal diet (control) group after receiving the non surgical periodontal treatment (with periodontal Gracey curettes and ultrasonic scaler) will continue with their current diet.Normal diet group will need 5 visits.
Study: NCT04936074

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle preserving selective laminectomy
Description: Muscle-preserving selective laminectomy differ from traditional laminectomy by the spinous process split that preserves the deep extensor muscles. The bilateral facet joints are not exposed. After the laminectomy is finished the split fragments of the spinous process are sutured together so that the deep extensor muscles are restored.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laminectomy with instrumented fusion
Description: A traditional laminectomy is complemented with lateral mass and/or pedicle screws connected with rods.
Study: NCT05960916

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Densah® burs
Description: Osseodensification is a non-excavating implant site preparation technique, it creates a densified layer of surrounding bone through compaction autografting while simultaneously plastically expanding the bony ridge at the same time facilitating for placement of large diameter implants and also avoiding fenestration and dehiscence defects.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Burs
Description: Conventional burs is the gold standard that used to prepare the osteotomy site by drilling of the bone and creating a bed for implant placement, it is used according to the manufacturer instructions.
Study: NCT05540912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D064+D701
Description: Reference

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D064+D701
Description: Reference
Study: NCT05913336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosilate
Description: Loading dose: 0.08mg/kg , Maintenance dose: IV remimazolam tosilate, dose range 0-2.0mg/kg/h, increment or decrement of 0.1-0.2mg/kg/h